ArticleScientific reports2023
EEG resting-state networks in Alzheimer's disease associated with clinical symptoms.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- The EEG analysis and identification of Alzheimer's disease: a review.Frontiers in aging neuroscience · 2025Pooled it
- Capturing silent oxidative stress in early Alzheimer's disease: prediction of CSF biomarkers from sleep qEEG data.GeroScience · 2026Article
- Article
- The mechanisms and strategies for Alzheimer's disease prevention: An update.Acta pharmaceutica Sinica. B · 2026Review
- PyCaret machine learning library with three preprocessing steps after eLORETA source estimation predicts Alzheimer's disease.Neuroimage. Reports · 2026Article
- Neural Oscillatory Mechanisms Underlying Step Accuracy: Integrating Microstate Segmentation with eLORETA-Independent Component Analysis.Brain sciences · 2025Article
- Electroencephalogram (EEG) Based Fuzzy Logic and Spiking Neural Networks (FLSNN) for Advanced Multiple Neurological Disorder Diagnosis.Brain topography · 2025Article
- EEG biomarkers in Alzheimer's and prodromal Alzheimer's: a comprehensive analysis of spectral and connectivity features.Alzheimer's research & therapy · 2024Article
- Disrupted brain functional connectivity as early signature in cognitively healthy individuals with pathological CSF amyloid/tau.Communications biology · 2024Article
- From Gut Microbiota to Brain Waves: The Potential of the Microbiome and EEG as Biomarkers for Cognitive Impairment.International journal of molecular sciences · 2024Review
- Detection of neurophysiological markers of cognitive reserve: an EEG study.Frontiers in aging neuroscience · 2024Article
- Neurophysiological markers in community-dwelling older adults with mild cognitive impairment: an EEG study.Alzheimer's research & therapy · 2023Article
- Entropy-Based Machine Learning Model for Fast Diagnosis and Monitoring of Parkinson's Disease.Sensors (Basel, Switzerland) · 2023Article
- Resting-State Functional Connectivity Difference in Alzheimer's Disease and Mild Cognitive Impairment Using Threshold-Free Cluster Enhancement.Diagnostics (Basel, Switzerland) · 2023Article
- Brain network analysis in Alzheimer's disease and mild cognitive impairment using high-density diffuse optical tomography.Imaging neuroscience (Cambridge, Mass.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a progressive neuropsychiatric disease affecting many elderly people and is characterized by progressive cognitive impairment of memory, visuospatial, and executive functions. As the elderly population is growing, the number of AD patients is increasing considerably. There is currently growing interest in determining AD's cognitive dysfunction markers. We used exact low-resolution-brain-electromagnetic-tomography independent-component-analysis (eLORETA-ICA) to assess activities of five electroencephalography resting-state-networks (EEG-RSNs) in 90 drug-free AD patients and 11 drug-free patients with mild-cognitive-impairment due to AD (ADMCI). Compared to 147 healthy subjects, the AD/ADMCI patients showed significantly decreased activities in the memory network and occipital alpha activity, where the age difference between the AD/ADMCI and healthy groups was corrected by linear regression analysis. Furthermore, the age-corrected EEG-RSN activities showed correlations with cognitive function test scores in AD/ADMCI. In particular, decreased memory network activity showed correlations with worse total cognitive scores for both Mini-Mental-State-Examination (MMSE) and Alzheimer's Disease-Assessment-Scale-cognitive-component-Japanese version (ADAS-J cog) including worse sub-scores for orientation, registration, repetition, word recognition and ideational praxis. Our results indicate that AD affects specific EEG-RSNs and deteriorated network activity causes symptoms. Overall, eLORETA-ICA is a useful, non-invasive tool for assessing EEG-functional-network activities and provides better understanding of the neurophysiological mechanisms underlying the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.